Dr. Ramesh K. Moolani, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
855 3rd Ave Ste 3330
Chula Vista, CA 91911
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 279
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license C149851 (first issued 2017; current) · MI license 4301083830 -
Internal Medicine Physician
MI license 4301083830
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Scripps Mercy Hospital San Diego, CA
- Sharp Chula Vista Medical Center Chula Vista, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 279
- Services billed
- 133,124
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 6,450 | 12 |
| Injection, denosumab, 1 mg | 5,040 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,412 | 24 |
| Injection, palonosetron hcl, 25 mcg | 811 | 20 |
| Insertion of needle into vein for collection of blood sample | 755 | 231 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 468 | 13 |
| Administration of chemotherapy into vein, 1 hour or less | 260 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 218 | 79 |
| Injection of drug or substance under skin or into muscle | 211 | 36 |
| Injection, zoledronic acid, 1 mg | 198 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Chula Vista, CA | 189 |
| Omeprazole Other prescribers in Chula Vista, CA | 90 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Chula Vista, CA | 81 |
| Ondansetron Odt (ondansetron) Other prescribers in Chula Vista, CA | 70 |
| Anastrozole Other prescribers in Chula Vista, CA | 46 |
| Naproxen Other prescribers in Chula Vista, CA | 45 |
| Imbruvica (ibrutinib) | 35 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Chula Vista, CA | 35 |
| Dexamethasone Other prescribers in Chula Vista, CA | 34 |
| Lenalidomide | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 44 companies reported 185 payments worth $5,111 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,257 |
|---|---|
| Merck Sharp & Dohme LLC | $398 |
| Janssen Biotech, Inc. | $366 |
| E.r. Squibb & Sons, L.l.c. | $258 |
| AstraZeneca Pharmaceuticals LP | $227 |
| Pfizer Inc. | $225 |
| AbbVie Inc. | $219 |
| Sobi, Inc | $193 |
| Food and Beverage | $3,931 |
|---|---|
| Long term medical supply or device loan | $1,000 |
| Education | $181 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 1, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Gilead Sciences, Inc. Dec 2, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4221936;G360;10027379 | $12.42 |
| Janssen Biotech, Inc. Dec 1, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Agios Pharmaceuticals, Inc. Oct 22, 2025 | Education PYRUKYND · Genetically Defined Disease · in-kind | $68.10 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.